Engineering Lineage Potency and Plasticity of Stem Cells using Epigenetic Molecules

Area of Science:

• Biochemistry
• Cell Biology
• Regenerative Medicine

Background:

• Stem cells offer regenerative potential but face challenges in lineage-specific differentiation.
• Epigenetic regulation is a key factor influencing stem cell developmental pathways.
• Modulating epigenetic molecules may overcome limitations in human stem cell differentiation.

Purpose of the Study:

• To identify epigenetic small molecules that can modulate osteogenesis in human mesenchymal stem cells (hMSCs).
• To investigate the potential of these molecules to enhance or inhibit bone formation in vitro.
• To evaluate the efficacy of identified molecules in promoting osteogenic differentiation in hMSCs from aged donors.

Main Methods:

• Screening of 84 small molecule pharmacological agents targeting nucleosomal modification.
• In vitro assessment of molecule effects on hMSC osteogenesis and cell viability.
• Testing of lead compounds on hMSCs derived from aged human donors.

Main Results:

• A subset of molecules was identified that significantly influenced osteogenesis in hMSCs.
• Gemcitabine and Chidamide maximally enhanced osteogenesis by 5.9- and 2.3-fold, respectively, in aged hMSCs.
• Several molecules were found to maximally inhibit osteogenesis, while others maintained cell viability.

Conclusions:

• Small epigenetic molecules can effectively regulate the lineage plasticity of bone-marrow derived mesenchymal stem cells.
• Identified molecules, such as Gemcitabine and Chidamide, demonstrate potential for therapeutic applications in bone regeneration.
• Modulating the epigenetic profile of hMSCs offers a promising strategy for regenerative medicine.